News

San Diego, USA and Cambridge, UK, 12 June, 2019: Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and PhoreMost Limited today announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target.

Medicines Discovery Catapult and Waters partner to support UK medicines discovery with advanced technology solutions


Today [12 June], Medicines Discovery Catapult announce the launch of a strategic partnership with Waters Corporation, a world leading mass spectrometry manufacturer.


The partnership will give small and medium enterprises (SMEs) working with Medicines Discovery Catapult unprecedented access to brand-new mass spectrometry technologies which are not yet fully commercially available.

An Innovation Day focused on the future of mobility has enabled leading global automotive supplier Magna International to make important connections with researchers, start-ups and companies in and around Cambridge.

The increasing popularity of the human microbiome in biotech has become a source of scientific and investor excitement in recent years. Microbiomes, or the genes of a community of microbial cells (or microbiota) which the body is host to, have unexpected benefits and implications for overall health, from regulating the immune system, to influencing conditions such as obesity, diabetes, cancer and aging.

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.

Astex welcomes positive, new data showing breast cancer drug, Kisqali® (ribociclib), cuts risk of death by up to a third when given with hormone therapy

• Cedazuridine and decitabine, administered orally as a fixed-dose combination (ASTX727), met the primary endpoint of decitabine exposure equivalence of total 5-day dosing between oral ASTX727 and IV decitabine in the phase 3 ASCERTAIN study in MDS and CMML patients

• The study confirmed that the safety profile and clinical activity of the cedazuridine and decitabine fixed-dose combination was similar to that observed in the phase 1/2 study and similar to the expected clinical profile of decitabine IV

To view the June 2019 eNews click here


Instinctif Partners’ Corporate and Capital Markets practice has made two Managing Partner promotions in its UK business.


Nick Woods, who leads the Financial Services team, has become the company’s youngest ever Managing Partner, while Melanie Toyne-Sewell has been promoted within the firm’s Life Sciences team.

Cambridge, 3 June 2019: PIR is delighted to announce the appointment of highly regarded executives to support its planned international expansion. 

 

From today, PIR life sciences executive search and interim management will be joined by Tom Bradley and Stuart Penney as Senior Partners, Gemma Adamante as Senior Executive Researcher and George Owen as Executive Researcher. 

 

These valuable additions to an already strong team will fuel the PIR drive to expand internationally within the life sciences sector.  

 

Pages